Clinical Trial Of Potential COVID-19 Cure RLF-100 To Be Expanded

Relief Therapeutics announced that it is expanding clinical trials for it's potential COVID-19 cure, RLF-100, to include patients receiving high flow oxygen and noninvasive ventilation (CPAP), in addition to those on ventilators. In a statement, Relief Therapeutics said that the trial is being led by NeuroRx, Inc., the US development partner of Relief Therapeutics.

As leading hospitals are avoiding mechanical ventilators, the firm decided to extend the clinical trial to patients on other forms of treatment for respiratory failure. RLF-100, also known as Aviptadil, has been used in successful trials for sarcoidosis, pulmonary fibrosis, asthma/allergy, and pulmonary hypertension.